Compare TransMedics Group Inc (TMDX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Wendys Co — how do they compare? TransMedics Group Inc trades at $87.58 (market cap $3.10B), while Wendys Co trades at $8.63 (market cap $1.44B). The key difference: TransMedics Group Inc is far larger — about 2.2× Wendys Co's market cap, and Wendys Co pays a 3.71% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WEN | |
|---|---|---|
Market Cap | $3.10B | $1.44B |
Sector | Technology | Consumer Cyclical |
52-Week High | $150.42 | $10.68 |
52-Week Low | $61.99 | $6.17 |
Enterprise Value | $3.49B | $5.17B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Wendy's (WEN) stock is trading at $8.57, up 17.4% in 24 hours, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 EPS of $0.18, beating expectations, but faces challenges including a 50% dividend cut, withdrawn 2026 outlook, and declining U.S. same-store sales as Burger King overtakes it as the second-largest U.S. burger chain. Financial metrics show a P/E of 11.44 and ROE of 108.04%, but net income margin has fallen to 5.72% for 2026.
The outlook is cautious; while valuation appears reasonable and recent earnings beats are positive, significant operational headwinds, high debt, and intense competition pose risks. Analyst sentiment is mixed with a majority Hold rating, reflecting uncertainty around the new CEO's turnaround plan. Investment opportunity hinges on successful execution of strategic initiatives to restore growth and profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
